Weekly Updates & Resources from CHUG

image.jpg

BAMLANIVIMAB USED AS EARLY STRATEGY FOR ILLINOIS CRITICAL CARE FACILITIES

On, November 6th, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) of bamlanivimab for high-risk COVID-19 patients.

The new strategy requires weekly allocations to be released with prioritization of Safety Net Hospitals, Critical Access Hospitals, and consideration for ICU patients.

  • During the week of November 23rd, 2020, 2,930 vials were allocated

  • During the week of November 30th, 2020, the state of Illinois was allocated 3,160 vials of Eli Lilly’s bamlanivimab and 2,280 vials of Regeneron’s casiriv for antibody treatment